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Aim of study
The aim of this study was to evaluate the frequency of
pathological complete response (pCR) in BRCA1 muta-
tion carriers diagnosed with breast cancer treated with
preoperative Cisplatin chemotherapy.
Material and methods
Between December 2006 and August 2011 seventy five
women with BRCA1 mutation and diagnosed with
breast cancer stage I to III were enrolled. Patients were
treated with Cisplatin at dose 75 mg/m2 every three
weeks for four cycles. After chemotherapy mastectomy
was performed and followed with conventional che-
motherapy. Seven patients had prior chemotherapy for a
previous cancer diagnosis. Four patients received prior
chemotherapy for their current cancer diagnosis and
then received therapy according to our protocol.
In the group of 67 patients treated with Cisplatin in
first line of treatment - 32 met the standard criteria for
neoadjuvant chemotherapy, and in 35 cases - the criteria
were not met.
Pathologic complete response was determined by
review of surgical specimens. Complete pathologic
response was defined as no residual invasive disease in
both the breast and axilla. Information was collected on
clinical stage, grade, hormone receptor status and HER2
status prior to treatment.
Results
A pathologic complete response (pCR) was observed in
47/75 (62,7%) patients, partial response was observed in
27/75 (36%) patients and stable disease in 1/75 (1,3%)
patient. After excluding those patients who were treated
with chemotherapy in the past - pathological complete
response was achieved in 45/67 (67,2%) patients. In the
group of 25 patients who met the standard criteria for
neoadjuvant chemotherapy and treated with Cisplatin-
monotherapy as a first line of treatment pathological
complete response was achieved in 56% (14/25) patients.
In group of remaining 42 patients who did not meet the
criteria for neoadjuvant treatment the pathological com-
plete response was achieved in 78,6% (33/42) patients.
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